Skip to main content
logo
Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
7.91
+0.02 (0.25%)
Sep 16, 2026, 4:00 PM EDT - Market closed

Cartesian Therapeutics Revenue

Cartesian Therapeutics had revenue of $1.48M in the twelve months ending June 30, 2026, up 43.96% year-over-year. In the year 2025, Cartesian Therapeutics had annual revenue of $2.80M, down -92.81%.

Revenue (ttm)
$1.48M
Revenue Growth
+43.96%
P/S Ratio
162.03
Revenue / Employee
$19,693
Employees
75
Market Cap
239.32M

Revenue Chart

Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20252.80M-36.12M-92.81%
Dec 31, 202438.91M12.91M49.64%
Dec 31, 202326.00M-84.77M-76.53%
Dec 31, 2022110.78M25.70M30.21%
Dec 31, 202185.08M68.48M412.60%
Dec 31, 202016.60M9.92M148.57%
Dec 31, 20196.68M5.77M639.42%
Dec 31, 2018903.00K696.00K336.23%
Dec 31, 2017207.00K-7.88M-97.44%
Dec 31, 20168.08M2.07M34.47%
Dec 31, 20156.01M2.97M97.73%
Dec 31, 20143.04M1.56M105.54%
Dec 31, 20131.48M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Compugen74.00M
Foghorn Therapeutics36.74M
ProQR Therapeutics21.05M
Alector13.86M
Whitehawk Therapeutics7.15M
Entrada Therapeutics4.69M
Veraxa Biotech AG29.54K
Revenue Rankings

RNAC News

More News